LungLife AI, INC Participation in National Cancer Institute's EDRN
October 17 2022 - 2:00AM
RNS Non-Regulatory
TIDMLLAI
LungLife AI, INC
17 October 2022
LungLife AI, Inc.
(the "Company" or "LungLife")
LungLife to participate in the US National Cancer Institute's
Early Detection Research Network
LungLife AI (AIM: LLAI), a developer of clinical diagnostic
solutions for lung cancer, announces that based on the strength of
its technology it will be one of two industry partners to
participate in the Boston University ("BU") -University of
California Los Angeles ("UCLA") Lung Cancer Biomarker Development
Laboratory of the US National Cancer Institute's Early Detection
Research Network ("EDRN").
The EDRN is a division of the US National Cancer Institute, the
federal government's principal agency for cancer research and
training. The EDRN's mission is to discover, develop, and validate
new biomarkers and medical imaging technologies to detect
early-stage cancers, and to translate them into clinical tests. It
is comprised of over 300 investigators from academic institutions
and industry partners working collaboratively to bring new
diagnostic biomarkers to clinical use.
LungLife's clinical laboratory will operate as a Biomarker
Reference Laboratory, processing blood samples from the
participating academic centres at UCLA and BU where the LungLB(R)
test will be combined with imaging to assist their early detection
research, as well as validate combined test performance in patients
with indeterminate lung nodules. It is expected the blood samples
will be collected over a number of years with progress and results
presented to EDRN members at annual meetings, representing the
first independent study of LungLB(R). These activities are
independent of LungLife's ongoing pivotal validation study and do
not impact on the progress of this study.
The work of the EDRN closely aligns with LungLife's mission to
increase the early detection of lung cancer and will provide
further clinical evidence for the LungLB(R) technology as well as
widen awareness of our technology with leading US investigators. It
also affords LungLife the potential to offer novel cell-based
diagnostic biomarkers discovered at UCLA and BU to physicians from
its clinical laboratory, thereby potentially expanding its lung
cancer testing capabilities.
Paul Pagano, CEO for LungLife said: "We are excited that
LungLife will participate in such a prestigious national programme
aimed at bringing early detection technology to the clinic, and we
are delighted to work with UCLA and BU, two leading medical
research institutions with teams that have been pushing the field
forward to make important biomarkers available to patients."
Denise Aberle, MD, Professor of Radiology and Bioengineering,
Vice Chair for Research, Department of Radiological Sciences at
UCLA, EDRN Investigator said: "Lung cancer remains the deadliest
cancer because most people are diagnosed in later stages after
developing symptoms - the ability to detect lung cancer in early
stages could have a profound effect on patients' outcomes.
Cell-based biomarkers have considerable potential for early cancer
detection. When combined with imaging markers using artificial
intelligence/radiomics analysis of computed tomography, combined
imaging and cell-based approaches could substantially shift the
diagnosis of lung cancer to early stages when it is most
curable.
"We look forward to collaborating on this grant to evaluate
novel imaging and cell-based biomarkers in patients with
intermediate-risk indeterminate lung nodules, which are the most
diagnostically challenging nodules to evaluate and represent a
critical unmet need in early lung cancer detection."
BU's press release can be found at:
https://www.bumc.bu.edu/busm/news-events/
For further information please contact:
LungLife AI, Inc. www.lunglifeai.com
Paul Pagano, CEO Via Walbrook PR
David Anderson, CFO
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
Paul McManus / Alice Woodings / Phillip Mob: 07980 541 893 / 07407 804 654 /
Marriage 0 7867 984 082
About LungLife AI
LungLife AI is a developer of clinical diagnostic solutions
designed to make a significant impact in the early detection of
lung cancer, the deadliest cancer globally. Using a minimally
invasive blood draw, the Company's LungLB(R) test is designed to
deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit
www.lunglifeai.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAQZLFFLBLFFBB
(END) Dow Jones Newswires
October 17, 2022 02:00 ET (06:00 GMT)
Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From May 2024 to Jun 2024
Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From Jun 2023 to Jun 2024